abstrak2 epilepsi

7/23/2019 Abstrak2 Epilepsi

http://slidepdf.com/reader/full/abstrak2-epilepsi 1/6

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(3):20-6.

[Clinical importance of EEG changes during the treatment of epilepsy

with valproate (depakene chrono)]

[rti!le i" #$ssia"%

Zenkov L!

I" 2& 'atie"t ith e'ile's i" the a*e +o 6-&6 ears the ,, as st$ie /e+ore

treatme"t a" a+ter sta/iliatio" o+ the i"itial a" !orre!te oes o+ val'roate

(e'aki"e !hro"o). he ma"$al a"alsis ith the +ormalie $a"titative estimatio" o+

i"ees o+ e'ile'ti! a!tivit (,l) a" !om'$terie ma''i"* o+ s'e!tral 'oer i" the

mai" /a"s o+ ,, as !arrie o$t. I" 14 'atie"ts remissio" o+ a hal+-ear a" more

as a!hieve. vera*e ,l /e+ore treatme"t i" all *ro$' as 15.1 7- 1.89 o" the i"itial

sta/ilie oe (10-15 m*7k*7a)--&.3 7- 1.2 (' 0.000)9 at i"!rease o+ a oe 15

m*7k*7a9 o" the avera*e it as "ot reveale o+ the +$rther !ha"*e o+ ,l. here as

si*"i+i!a"t 'ositive !orrelatio" /etee" e'ile'ti! a!tivit i" ,,9 e'resse / ,l a"

"$m/er o+ atta!ks i" the 'atie"t 'er o"e mo"th o" the mome"t o+ ,, resear!h (r

0.659 t 6.54). I" 6 'atie"ts ith +arma!oresiste"!e the i"e o+ e'ile'ti! a!tivit as

si*"i+i!a"tl hi*her (,l 11.< 7- &.3)9 tha" i" the 'atie"ts ith *oo e++e!t (,l 1.8

7- 0.49 ' = 0.002). I" ata o+ the !om'$ter a"alsis $"er i"+l$e"!e o+ e'aki"e

!hro"o the re$!tio" o+ 'oer i" all /a"s a" leas as o/serve9 e!e't o!!i'ital

lo/es here the i"!rease o+ al'ha-'oer as o/serve. his re+le!ts re$!tio" o+

e'ile'ti! a!tivit a" restoratio" o+ "ormal ,,9 hi!h a!!om'a"ie the

im'roveme"t o+ so!ial a" 's!hi! aa'tatio". he res$lts o+ the st$ emo"strate

that a$tomate or ma"$al ,, !o"trol is im'orta"t +a!tor o+ !orre!t sele!tio" o+ a

val'roate oe $ri"* treatme"t9 that allos "ot o"l to s$''ress e++e!tivel the

atta!ks9 /$t o" the mi"imal /$t s$++i!ie"t oe to rea!h im'roveme"t o+ 's!ho-so!ial

+$"!tio"i"* a" to re$!e terms o+ treatme"t9 at the e'e"se o+ !o"trol o+ a"$"'rei!ta/le rela'se o+ atta!ks.

htt':77."!/i."lm."ih.*ov7e"tre7$er.+!*i>

!m#etrieve?/P$/@e?listA$is1185<3&1?o't/stra!t

B ,"o!ri"ol I"vest. 1843 $*;6(&):305-6.

Effects of sodium"valproate administration on plasma #C$% levels in

patients with #C$% hypersecretion!

#m&rosi ' 'ochicchio iva E *aglia G!

he e++e!ts o+ the a!$te ami"istratio" o+ soi$m-val'roate (&00 m* 'o) o" 'lasma

CD levels ere st$ie i" & 'atie"ts ith C$shi"*Es isease9 1 ith Nelso"Es

s"rome a" i" 3 ith iso"Es isease. No si*"i+i!a"t re$!tio" o+ !orti!otro'i"

!o"!e"tratio" as o/serve9 as !om'are to sali"e i"+$sio". hese ata o "ot +avor

the h'othesis o+ a" i"hi/itor role o+ soi$m-val'roate o" CD se!retio" i" s$!h

'atie"ts.


!m#etrieve?/P$/@e?listA$is6315406?o't/stra!t



+msrsa.+$k$i-me.a!.F'

GCK#HNJ: or am/$lator 'eiatri! o$t'atie"ts9re'orts o+ a/"ormalities o+

/o"e meta/olism asso!iate ith a"ti-e'ile'ti! r$*s are i"!o"siste"t a" ma /e

i++i!$lt to i"ter'ret. @,DHJS: he e++e!ts o+ lo"*-term a"ti-e'ile'ti! thera'

(mai"l val'roi! a!i a"7or !ar/amae'i"e) o" /o"e mi"eral stat$s ere eval$ate i"

am/$lator e'ile'ti! 'atie"ts(seve" males a" 11 +emales) a*e 5.5-15.8 ears.Go"emi"eral e"sit (G@J) at the l$m/ar s'i"e as meas$re / $al-e"er* L-ra

a/sor'tiometr a" markers o+ /o"e a" mi"eral meta/olism ere etermi"e.

#,SMS: he mea" G@J as e!rease / 8 i" o$r 'atie"ts relative to the

!o"trol9 a" +ive 'atie"ts (all males)shoe osteo'e"ia9 e+i"e as G@J SJ s!ores

less tha" - 1.5.Ser$m levels o+ mi"erals9 i"ta!t 'arathroi hormo"e a"

1al'ha925(HD)2 vitami" J ere ithi" the "ormal ra"*es. I" most 'atie"ts9 ser$m

levels o+ i"ta!t osteo!al!i"9 !ar/otermi"al 'ro'e'tie o+ t'e I 'ro!olla*e" a"

'rii"oli"e !ross-li"ke telo'e'tie o+ t'e I !olla*e" ere re$!e relative to the

!orres'o"i"* mea" !o"trol val$es. he GG *e"ot'e / GsmI restri!tio" +ra*me"t

le"*th 'olmor'hism9 asso!iate ith lo G@J9 as "ot +o$" i" o$r 'atie"ts. he

ietar !al!i$m i"take i" the osteo'e"i! 'atie"ts as si*"i+i!a"tl loer tha" that o+the "o"-osteo'e"i! 'atie"ts. CHNCMSIHNS: H$r res$lts i"i!ate that lo"*-term

a"ti-e'ile'ti! treatme"t i"$!es a state o+ e!rease /o"e t$r"over i" !hilre"9

res$lti"* i" osteo'e"ia 're+ere"tiall i" males. he alteratio"s ma /e $e9 at least i"

'art9 to ire!t e++e!ts o+ the r$*s o" /o"e !ells; a" that lo !al!i$m i"take !o$l /e

a" a**ravati"* +a!tor +or a"ti-e'ile'ti!-asso!iate osteo'e"ia.



Ne$ro's!ho/iolo*. 2002;&5(2):106-12.

Changes in &rain comple+ity during valproate treatment in patients

with partial epilepsy!

,im -. -ung ,/ Choi C.!

Je'artme"t o+ Ne$rolo*9 Colle*e o+ @ei!i"e9 Ch$"*"am Natio"al "iversit9

aeFo"9 Korea.

HGB,CIO,: he e++e!t o+ val'roate (OP) o" h$ma" ele!troe"!e'halo*ra'h

(,,) as st$ie $si"* "o"li"ear "ami!s a"alsis to i"vesti*ate !ha"*es i" /rai"

!om'leit. @,DHJS: e 'ro'ose a s'atial li"ear moe !om'leit (SM@C)meas$re to $a"ti+ the !om'leit o+ s'atial li"ear moes i" m$lti!ha""el ,,s.

Ni"e 'atie"ts ith !om'le 'artial sei$res ho ha "ot 'revio$sl /ee" e'ose to

a"tie'ile'ti! r$*s (,Js) ere i"!l$e i" this st$. ,i*htee"-!ha""el ,, ata

ere !olle!te /e+ore a" a+ter OP thera'. Cha"*es i" /rai" !om'leit ere

eami"e $si"* the 'ro'ose SM@C meas$re9 hi!h re+le!ts /rai" !om'leit.

i+tee" "ormal9 health s$/Fe!ts ere i"!l$e as a !o"trol *ro$'. o !om'are SM@C

ith s'e!tral a"alsis9 e 'er+orme s'e!tral a"alsis ithi" the !o"ve"tio"al

+re$e"! /a"s. #,SMS: S'e!tral a"alsis shoe that the 'atie"t *ro$' ha

e!rease relative 'oer o+ the al'ha2 /a" i" the <9 P39 H1 a" C& leas /e+ore

OP treatme"t a" a" i"!rease relative theta 'oer i" the H1 lea relative to the

!o"trol *ro$'. Doever9 "o si*"i+i!a"t !ha"*es o!!$rre i" a" lea at a" +re$e"! /a" a+ter OP treatme"t. he mea" SM@C val$e as si*"i+i!a"tl loer i" the

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11982890&dopt=Abstract






'atie"t *ro$' /e+ore treatme"t tha" i" the !o"trol *ro$' (' 0.026). he avera*e

SM@C val$e +or all 'atie"ts i"!rease a+ter treatme"t a" "eare that o+ the !o"trol

*ro$'9 altho$*h statisti!al si*"i+i!a"!e as "ot attai"e (' 0.0<&).

CHNCMSIHNS: hese res$lts s$**est that e'ile's 'atie"ts have i"teri!tal

a/"ormalities that are emo"strate / re$!e /rai" !om'leit9 a" that OP

'artiall reverses this tre". No"li"ear a"alsis o+ ,, ata ma /e $se+$l i"

eval$ati"* the e++e!t o+ ,Js. Co'ri*ht 2002 S. Kar*er 9 Gasel



I"t B Pharm. 2002 e/ 21;233(1-2):253-6.

Car&apenem anti&iotics inhi&it valproic acid transport in Caco"0 cell

monolayers!

$orii . $akiguchi / 12umi . *ukushima $ /okota .!

Je'artme"t o+ Cli"i!al Pharma!olo*9 ra$ate S!hool o+ Pharma!e$ti!al S!ie"!es9

he "iversit o+ ok$shima9 1-<4 Sho-ma!hi9 ok$shima <<0-45059 Ba'a".

he !o"!omita"t $se o+ !ar/a'e"em a"ti/ioti!s ith val'roi! a!i has /ee" 'rohi/ite

/e!a$se !ar/a'e"ems i"$!e a e!rease i" 'lasma !o"!e"tratio" o+ val'roi! a!i i"

e'ile'ti! 'atie"ts $ri"* val'roi! a!i thera'. H$r 'revio$s i" vivo st$ i" rats

'ro'ose that i"hi/itio" / !ar/a'e"em o+ the i"testi"al a/sor'tio" o+ val'roi! a!i

mi*ht /e a 'ossi/le me!ha"ism +or the r$*-r$* i"tera!tio". o emo"strate the

h'othesis9 e eami"e the e++e!ts o+ imi'e"em a" 'a"i'e"em o" i"testi"altra"se'ithelial tra"s'ort o+ val'roi! a!i $si"* Ca!o-2 !ell mo"olaers. Imi'e"em a"

'a"i'e"em i"hi/ite the tra"s'ort o+ [1&C%-val'roi! a!i a!ross the Ca!o-2 !ell

mo"olaers +rom a'i!al-to-/asolateral sie i" a !o"!e"tratio"-e'e"e"t ma""er9

altho$*h the ha "o e++e!t o" the $'take o+ [1&C%-val'roi! a!i / Ca!o-2 !ells. he

i"hi/itio" / the !ar/a'e"ems o+ the val'roi! a!i tra"s'ort as +o$" eve" he"

the ere ae to o"l the /asolateral sie. rom these res$lts9 the !ar/a'e"ems ma

i"hi/it the a/sor'tio" o+ val'roi! a!i at the /asolateral mem/ra"e o+ i"testi"al

e'ithelial !ells9 hi!h !o"tri/$tes to the e!rease i" 'lasma !o"!e"tratio" o+ val'roi!

a!i a+ter oral ami"istratio".

htt':77."!/i."lm."ih.*ov7e"tre7$er.+!*i>!m#etrieve?/P$/@e?listA$is1148<&28?o't/stra!t

Pol @erk$ri$s Mek. 2001 Je!;11(66):&40-3.

[.onitoring of renal function in epileptic children and teenagers treated

with valproic acid or car&ama2epine in concomitant therapy with

tiaga&ine]

[rti!le i" Polish%



%urkac2 . 3iela"%o4enska # 5r2echowska"-u2wenko , ,o2ik # 6nolt -!

Katera i Zakla armakolo*ii Kli"i!"eF kaemii @e!"eF e ro!lai$.

he aim o+ the st$ as the eval$atio" o+ the i"+l$e"!e o+ &-mo"th !o"!omita"t

tia*a/i"e (G) a" val'roi! a!i (OP) or !ar/amae'i"e (CGZ) thera' o" re"al

+$"!tio" o+ e'ile'ti! !hilre" a" tee"a*ers. I"itial 'arameter val$es9 i"i!ate o"re"al is+$"!tio"9 ere !om'are ith these o/tai"e a+ter OP a" G or CGZ a"

G thera' a" ith val$es i" health !hilre" a" tee"a*ers. I"vesti*atio" *ro$'

as !om'ose o+ 22 !hilre" a" tee"a*ers ith r$*-resista"t +o!al e'ile's. e

o/serve that i" the time o+ !o"!omita"t OP a" G thera' i"!rease the N7*

!reati"i"e a!tivit i"e. I" s'ite the +a!t o+ statisti!al si*"i+i!a"!e o+ these !ha"*es9

the ere "ot o$tsie the "ormal ra"*e. /eta 2-mi!ro*lo/$li" !o"!e"tratio"s i" $ri"e

o+ e'ile'ti! !hilre" treate ith OP i" mo"othera' /e+ore !o"!omita"t thera'

ith G ere hi*her tha" i" !o"trol *ro$'. hat i++ere"!e as statisti!all

si*"i+i!a"t. itio" o+ G to the thera' "ormalie this 'arameter. J$ri"*

!o"!omita"t OP a" G or CGZ a" G thera' e i"Et o/serve statisti!all

si*"i+i!a"t !ha"*es o+ 'arameters i"i!ati"* o" *lomer$lar is+$"!tio". I" the OPthera' /e+ore !o"!omita"t treatme"t ith tia*a/i"e the is+$"!tio" o+ t$/$les a"

*lomer$les as o/serve. H" the other sie i" the !o"!omita"t OP a" G thera'

the is+$"!tio" o+ t$/$les a" *lomer$les i"Et o!!$rre. e !a" !o"!l$e that

!o"!omita"t thera' OP or CGZ ith tia*a/i"e o"Et a++e!t the re"al +$"!tio" i"

!li"i!al si*"i+i!a"t ma""er. hera' ith OP !o$l leas to mi"imal is+$"!tio" o+

t$/$les hat is re'rese"te / i"!reasi"* o+ /eta 2-mi!ro*lo/$li" level i" $ri"e.


!m#etrieve?/P$/@e?listA$is114884&2?o't/stra!t

EpilepsiaVolume 42 Issue 11 Page 1387 - November 2001doi:10.1046/j.128-117.2001.30800.! Monotherapy versus Polytherapy for Epilepsy: A MulticenterDouble-Blind Randomized Study§Charles L. P. Deckers, Yechiel A. Hekster, * Antoine Keyser, Henk J. J. van Lier, * Harry Meinardi,and * Willy . !enier

Purpose: "o#o$%era&' %as bee# $%e gold s$a#dard i# e&ile&s' $rea$me#$ (or $%e las$ 20 'ears) &ar$l'be*ause o( $%e re&u$a$io# (or i#*reased $o!i*i$' o( &ol'$%era&'. +o,ever) mo#o$%era&' a#d &ol'$%era&'%ave #o$ bee# *om&ared i# a double-bli#d *li#i*al $rial. &e# $rials $%a$ *om&ared $%e $,o $rea$me#$s,ere #o$ o&$imall' desig#ed a#d *om&ared $%e $,o a$ u#eual drug loads i.e.) a$ #o#euivale#$

dosages. e re&or$ o# a double-bli#d *li#i*al $rial i# ,%i*% a *ombi#a$io# o( *arbamae&i#e 5 a#dval&roa$e VP ,as *om&ared ,i$% 5 mo#o$%era&'. Pa$ie#$s s$ar$ed ,i$% eual drug loads) a#d#euro$o!i*i$' ,as $%e &rimar' ou$*ome measure.

Methods: %e 130 adul$ &a$ie#$s ,i$% u#$rea$ed ge#eralied $o#i* *lo#i* a#d/or &ar$ial seiures ,erera#domied $o eual drug loads o( ei$%er mo#o$%era&' 400 mg 5 &er da' or &ol'$%era&' 200 mg5 &lus 300 mg VP &er da'. u$*ome ,as measured b' seiure *ou#$s) *li#ime$ri* e&ile&s' s*ales)a#d #euro&s'*%ologi*al $es$s a$ baseli#e) a$ 2 a#d 12 mo#$%s) a#d irregularl' be$,ee# 2 a#d 12 mo#$%s.

Results: No s$a$is$i*al di((ere#*es ,ere (ou#d be$,ee# $%e $,o $rea$me#$s i# $%e redu*$io# o( seiure(reue#*ies) i# overall #euro$o!i*i$') or i# overall s's$emi* $o!i*i$'. %e (reue#*ies a#d *li#ime$ri*s*ores o( *er$ai# adverse e((e*$s did di((er e.g.) more mo#o$%era&' &a$ie#$s remai#ed seda$ed) a#dmore &ol'$%era&' &a$ie#$s gai#ed ,eig%$. e,er &ol'$%era&' &a$ie#$s ,i$%dre, be*ause o( adversee((e*$s 14 vs. 229) al$%oug% $%is did #o$ rea*% s$a$is$i*al sig#i(i*a#*e & 0.1. Neuro&s'*%ologi*al

assessme#$ did #o$ s%o, sig#i(i*a#$ di((ere#*es.



http://popup%28%27citart1%27%2C%27a4%27%2C%2710.1046/j.1528-1157.2001.30800.x','aj15281157200130800x','')
















onclusions: No di((ere#*es ,ere (ou#d i# overall #euro$o!i*i$' be$,ee# mo#o$%era&' a#d&ol'$%era&'.

EpilepsiaVolume 44 Issue s10 Page 21 - *$ober 2003doi:10.1046/j.128-117.44.s10.1.!

!vervie" of Studies to Prevent Posttraumatic Epilepsy

"ttore #e$hi

Summary: P%r&ose' Preve#$io# o( &os$$rauma$i* e&ile&s' P; is o( &rimar'im&or$a#*e $o redu*e $%e degree o( (u#*$io#al morbidi$' (ollo,i#g $rauma$i* brai# i#jur'I. +o,ever) $%e e((e*$s o( a#$ie&ile&$i* drugs ;<s i# &a$ie#$s ,i$% I mus$ beassessed se&ara$el' i# $erms o( &reve#$io# a#d *o#$rol o( &rovo=ed seiures ,%i*%i#*lude immedia$e a#d earl' &os$$rauma$i* seiures a#d &reve#$io# o( subseue#$u#&rovo=ed seiures la$e &os$$rauma$i* seiures or P;.

Methods' Po$e#$ial me*%a#isms (or &reve#$io# o( e&ile&$oge#esis as ,ell as re&or$sa#d s's$ema$i* revie,s ,ere evalua$ed $o de$ermi#e s$ra$egies a#d resul$s o( a$$em&$s

$o redu*e or &reve#$ $%e develo&me#$ o( e&ile&s' (ollo,i#g I.

!es%lts' I# observa$io#al s$udies) a($er a &eriod ra#gi#g (rom 6 mo#$%s $o 13 'ears) $%e&ro&or$io# o( *ases develo&i#g seiures ,as 0-109 i# &a$ie#$s re*eivi#g $rea$me#$*om&ared $o 2 09 i# $%ose ,%o ,ere le($ u#$rea$ed. I# ra#domied *li#i*al $rials) $%edi((ere#*e be$,ee# a*$ive $rea$me#$ >&%e#'$oi# P+) &%e#obarbi$al) or*arbamae&i#e 5? a#d &la*ebo ,as less remar=able a($er a (ollo,-u& ra#gi#g (rom3 $o 60 mo#$%s a#d ,as vir$uall' la*=i#g (or $%e &reve#$io# o( P;. I# a o*%ra#es's$ema$i* revie, o( 8@0 &a$ie#$s (rom 10 As assessi#g P+ or 5) $%e &ooledrela$ive ris= AA (or &reve#$io# o( earl' seiures ,as 0.33 @9 I 0.21 0.2. '*o#$ras$) $%e AA (or &reve#$io# o( la$e seiures ,as 1.28 @9 I 0.@0 1.81. "or$ali$'a#d #eurologi*al disabili$' ,ere similar i# $%e $,o $rea$me#$ grou&s. %e use o( P+,as (ollo,ed b' a# i#*reased #o#sig#i(i*a#$ ris= o( s=i# ras%es. I# addi$io#) *og#i$ive&er(orma#*e ,as sig#i(i*a#$l' a((e*$ed b' P+ i# severel' i#jured &a$ie#$s a$ 1 mo#$%

a#d $rea$me#$ ,i$%dra,al ,as (ollo,ed b' im&roveme#$ i# *og#i$ive (u#*$io#.

Concl%sions' %e (ailure $o i#(lue#*e $%e ris= o( P; i# s$udies o( &a$ie#$s ,i$% I aresimilar $o (i#di#gs o( me$a-a#al'sis o( ra#domied *li#i*al $rials o# seiure &reve#$io# i#o$%er *o#di$io#s) su*% as (ebrile seiures) *erebral malaria) *ra#io$om') a#d e!*essiveal*o%ol i#$a=e. or $%ese reaso#s) $%e &ro&%'la*$i* use o( ;<s s%ould be s%or$-las$i#ga#d limi$ed $o $%e &reve#$io# o( immedia$e a#d earl' seiures. %ro#i* $rea$me#$ s%ouldbe *o#sidered o#l' a($er a diag#osis o( P;.

her Jr$* @o"it. 2003 B$";25(3):2<8-46.

7opulation pharmacokinetics of car&ama2epine in Chinese

epilepsy patients!

-iao Z Zhong ., 8hi 9- %u . Zhang -%!

D$a Sha" Dos'ital9 $ Ja" "iversit9 Sha"*hai9 Peo'leEs #e'$/li! o+ Chi"a.

I@: o i"vesti*ate the 'harma!oki"eti! 'ro+ile o+ !ar/amae'i"e (CGZ) i"

Chi"ese e'ile's 'atie"ts. @,#IMS NJ @,DHJS: Ser$m sam'les

thro$*h !o"!e"tratio"s at stea state (" 64<) ere !olle!te 'ros'e!tivel

+rom 545 'atie"ts $ri"* ro$ti"e !li"i!al !are. Jata ere a"ale / the "o"-li"ear mie-e++e!t moeli"* (NHN@,@) te!h"i$e ith a o"e-!om'artme"t

http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3159&uid=12766553&db=PubMed&url=http://content.wkhealth.com/linkback/openurl?issn=0163-4356&volume=25&issue=3&spage=279



moel o+ +irst-orer a/sor'tio" a" elimi"atio". #,SMS: he im'orta"t

etermi"a"ts o+ !leara"!e (CM) ere total /o ei*ht (G); ose; 'atie"t

a*e over 65 ears (,); a" !omei!atio" ith 'he"toi" (PD)9 'he"o/ar/ital

(PG)9 or val'roi! a!i (OP) he" OP ail ose as *reater tha" 14 m*7k*.

he +i"al 'harma!oki"eti! moel +or relative CM a" a''are"t istri/$tio"

vol$me (O) ere: ,$atio" CHNCMSIHN: 'o'$latio" 'harma!oki"eti!

moel as 'ro'ose to estimate the i"ivi$al CM +or Chi"ese 'atie"ts

re!eivi"* CGZ i" terms o+ 'atie"tEs ose9 G9 a" !omei!atio"s to esta/lisha 'riori osa*e re*ime"s.

P@IJ: 12<66553 [P$/@e - i"ee +or @,JMIN,%

abstrak2 epilepsi

Documents